The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease
HMGCoA-inhibitors (statins) lower plasma cholesterol through interference with the rate-limiting enzyme in the endogenous synthesis process. Since their introduction in the early 90’s, the clinical attitude towards cardiovascular (cv) risk reduction has evolved from the attention to single risk fact...
| Hlavní autoři: | , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
SEEd Medical Publishers
2006-09-01
|
| Edice: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Témata: | |
| On-line přístup: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/261 |